239 related articles for article (PubMed ID: 22897825)
1. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
2. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
3. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
4. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency.
Yamashita T; Seino Y; Ogawa A; Ogata K; Fukushima M; Tanaka K; Mizuno K
J Cardiol; 2010 May; 55(3):377-83. PubMed ID: 20350516
[TBL] [Abstract][Full Text] [Related]
5. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
[TBL] [Abstract][Full Text] [Related]
6. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
7. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy.
Kouloubinis A; Kaklamanis L; Ziras N; Sofroniadou S; Makaritsis K; Adamopoulos S; Revela I; Athanasiou A; Mavroudis D; Georgoulias V
Int J Cardiol; 2007 Nov; 122(3):195-201. PubMed ID: 17289172
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
11. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
[TBL] [Abstract][Full Text] [Related]
12. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
[TBL] [Abstract][Full Text] [Related]
13. Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major.
Delaporta P; Kattamis A; Apostolakou F; Boiu S; Bartzeliotou A; Tsoukas E; Papassotiriou I
Blood Cells Mol Dis; 2013 Jan; 50(1):20-4. PubMed ID: 23017692
[TBL] [Abstract][Full Text] [Related]
14. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
15. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
[TBL] [Abstract][Full Text] [Related]
16. Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction.
Arikan S; Tuzcu A; Gokalp D; Bahceci M; Danis R
Clin Endocrinol (Oxf); 2007 Aug; 67(2):202-7. PubMed ID: 17547691
[TBL] [Abstract][Full Text] [Related]
17. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
[TBL] [Abstract][Full Text] [Related]
19. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
[TBL] [Abstract][Full Text] [Related]
20. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
